StockNews.AI
LTRN
StockNews.AI
4 hrs

IBN Announces Latest Episode of The BioMedWire Podcast Featuring Panna Sharma, CEO of AI-Driven Biotech Focused on Challenging & Rare Cancers, Lantern Pharma Inc. (LTRN)

1. Panna Sharma discusses LTRN's AI-driven cancer drug development approach. 2. Three clinical trials for potential billion-dollar drugs are underway. 3. AI methods could significantly reduce cancer drug development costs and time. 4. Recent brain cancer approvals signal a new era in oncology advancements. 5. LTRN plans to tackle difficult cancer types in the coming years.

8m saved
Insight
Article

FAQ

Why Bullish?

LTRN's focus on AI-driven oncology positions it for potential market disruption. Similar biotech firms have seen stock increases following successful trial results.

How important is it?

The article provides insights into LTRN's ongoing clinical trials and innovative technology, likely to affect investor sentiment positively.

Why Long Term?

The establishment of AI approaches and ongoing clinical trials suggest prolonged influence on LTRN's market position.

Related Companies

XBIIBBNVCREDITCRSP
AUSTIN, Texas, Sept. 10, 2025 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features Panna Sharma, President, CEO, and Director of Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted cancer therapies using its proprietary RADR® AI platform. Mr. Sharma explains the mechanisms of the drug and also provides insights into the three ongoing clinical trials for each of the potential drug-candidates that could be worth several billion USD each. During the interview, Sharma explained Lantern Pharma’s core mission and AI-driven approach. “We like to think of ourselves as an AI-first company focused on creating cancer medicines. The problem that we’re trying to solve is a massive problem globally: about $250 billion a year is spent on research and development into new cancer medicines, yet it takes 10-to-12 years to go from an idea to an approved drug, and 93% of them fail… To me, this is a perfect problem area for top cancer minds to try to use AI, big data and computational biology to solve. That’s what our team does.” “We’re maniacally focused on driving AI first. We’ve created computational models from the ground up to focus on different types of cancers and the mechanisms behind them… Imagine being able to aggregate world-class cancer research 24 hours a day and have machine learning models compete to answer complex questions. That’s exactly what we’re doing — using AI to tackle the challenge of creating cancer medicines, with three drug candidates now dosing patients in Japan, Taiwan, and the United States.” Looking ahead, Sharma highlighted Lantern’s market positioning and outlook. “The next five to seven years, I see this as an era where many of the most difficult cancers, specifically brain cancers, we’re going to start solving for them. We recently announced a new board member who came from a brain cancer company that just got acquired, and their drug was recently approved… That was one of three brain cancer drugs approved in the last 12-to-14 months (after 17 years without any approvals) signaling a new era in precision neuro-oncology.” Join IBN’s Stuart Smith and Panna Sharma, President, CEO, and Director of Lantern Pharma, to learn more about the company’s AI-powered precision oncology platform, pipeline milestones, and vision for transforming cancer treatment. To hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com The latest installment of The BioMedWire Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 18 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies. To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine About Lantern Pharma Lantern Pharma is an AI company transforming the cost, time, and failure rate of oncology drug discovery and development. Lantern's proprietary AI platform RADR® uses machine learning and multiomic data to solve complex, billion-dollar drug development challenges. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, Lantern has built a pipeline of promising, clinical stage drug candidates, including molecules that target novel cancer mechanisms and targets. For more information, visit the company’s website at www.LanternPharma.com About IBN IBN consists of financial brands introduced to the investment public over the course of 18+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients. Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions. For more information, please visit https://www.InvestorBrandNetwork.com Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer Forward-Looking Statements This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements. Corporate Communications IBNAustin, Texaswww.InvestorBrandNetwork.com512.354.7000 OfficeEditor@InvestorBrandNetwork.com

Related News